AIRLINK 197.97 Decreased By ▼ -3.27 (-1.62%)
BOP 10.04 Increased By ▲ 0.07 (0.7%)
CNERGY 7.29 Increased By ▲ 0.40 (5.81%)
FCCL 36.00 Increased By ▲ 0.64 (1.81%)
FFL 16.91 Decreased By ▼ -0.24 (-1.4%)
FLYNG 25.04 Increased By ▲ 0.83 (3.43%)
HUBC 134.03 Decreased By ▼ -4.16 (-3.01%)
HUMNL 14.14 Increased By ▲ 0.07 (0.5%)
KEL 4.78 Decreased By ▼ -0.08 (-1.65%)
KOSM 6.94 Increased By ▲ 0.28 (4.2%)
MLCF 44.98 Decreased By ▼ -1.33 (-2.87%)
OGDC 218.23 Decreased By ▼ -4.31 (-1.94%)
PACE 6.94 Decreased By ▼ -0.12 (-1.7%)
PAEL 41.42 Decreased By ▼ -1.72 (-3.99%)
PIAHCLA 16.86 Decreased By ▼ -0.17 (-1%)
PIBTL 8.46 Decreased By ▼ -0.08 (-0.94%)
POWER 9.39 Increased By ▲ 0.29 (3.19%)
PPL 185.93 Decreased By ▼ -2.83 (-1.5%)
PRL 41.27 Decreased By ▼ -2.00 (-4.62%)
PTC 24.77 Decreased By ▼ -0.58 (-2.29%)
SEARL 104.65 Decreased By ▼ -5.77 (-5.23%)
SILK 1.01 Decreased By ▼ -0.02 (-1.94%)
SSGC 40.91 Decreased By ▼ -1.73 (-4.06%)
SYM 18.05 Decreased By ▼ -0.52 (-2.8%)
TELE 8.91 Decreased By ▼ -0.21 (-2.3%)
TPLP 12.84 Decreased By ▼ -0.84 (-6.14%)
TRG 66.60 Decreased By ▼ -1.56 (-2.29%)
WAVESAPP 11.30 Increased By ▲ 1.03 (10.03%)
WTL 1.78 Decreased By ▼ -0.09 (-4.81%)
YOUW 4.00 Decreased By ▼ -0.01 (-0.25%)
BR100 12,077 Decreased By -142.4 (-1.17%)
BR30 36,524 Decreased By -793.3 (-2.13%)
KSE100 115,042 Decreased By -802.6 (-0.69%)
KSE30 36,200 Decreased By -276.6 (-0.76%)

GENEVA: The AstraZeneca-Oxford Covid-19 vaccine can be used for people aged over 65, and also where coronavirus variants of concern are circulating, WHO experts said Wednesday, soothing fears about the jab.

The World Health Organization’s 15-member Strategic Advisory Group of Experts on Immunization (SAGE) issued interim recommendations for when and how to use the two-shot vaccine, which has yet to receive WHO emergency use authorisation.

The announcement came after the vaccine suffered several setbacks, raising questions about whether it was appropriate to use it on older people, or in places where a variant of the virus first found in South Africa is circulating.

SAGE chief Alejandro Cravioto acknowledged the lack of data on the vaccine’s efficacy for people aged over 65, which has prompted a number of countries to withhold recommending its use in older people — who are by far the most vulnerable to the virus.

But, he told journalists, “we feel that the response of this group cannot be any different from groups of a younger age”.

SAGE, he said, recommends “for the vaccine to be used for 18 years and above without an upper age limit”.

He said the experts were eagerly awaiting more specific data on the efficacy of the vaccine in people over 65, but said it “would not be appropriate” to wait with its recommendations.

“We have thousands of people dying,” he stressed.

Comments

Comments are closed.